Clinical Trials Directory

Trials / Completed

CompletedNCT04064125

Dermal Cumulative Irritant Patch Study

A 21-Day, Randomized, Controlled Study to Evaluate the Skin Irritation Potential of FMX-101 in Healthy Volunteers Using a Cumulative Irritant Patch Test Design

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
42 (actual)
Sponsor
Vyne Therapeutics Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

A 21-Day, Randomized, Controlled Study to Evaluate the Skin Irritation Potential of FMX-101 in Healthy Volunteers Using a Cumulative Irritant Patch Test Design

Conditions

Interventions

TypeNameDescription
DRUGFMX-101

Timeline

Start date
2016-09-01
Primary completion
2016-09-28
Completion
2016-10-28
First posted
2019-08-21
Last updated
2019-08-28

Regulatory

Source: ClinicalTrials.gov record NCT04064125. Inclusion in this directory is not an endorsement.